{"product_id":"antibodysystem-kdd06801","title":"Andecaliximab ELISA Kit","description":"\u003cp\u003e\u003cstrong\u003eCatalog No.\u003c\/strong\u003e: KDD06801\u003c\/p\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCatalog No.\u003c\/th\u003e\n\u003ctd\u003eKDD06801\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct name\u003c\/th\u003e\n\u003ctd\u003eAndecaliximab ELISA Kit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003ctd\u003e96 T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStability and Storage\u003c\/th\u003e\n\u003ctd\u003eThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eDetection method\u003c\/th\u003e\n\u003ctd\u003eColorimetric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePrecision\u003c\/th\u003e\n\u003ctd\u003eCV\u0026lt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSample type\u003c\/th\u003e\n\u003ctd\u003ePlasma, Serum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAssay type\u003c\/th\u003e\n\u003ctd\u003eQuantitative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSensitivity\u003c\/th\u003e\n\u003ctd\u003e0.156 μg\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRange\u003c\/th\u003e\n\u003ctd\u003e0.31-5 μg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRecovery\u003c\/th\u003e\n\u003ctd\u003e80-120%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBackground\u003c\/th\u003e\n\u003ctd\u003eAndecaliximab (formerly GS-5745; Gilead Sciences, Inc.), a recombinant chimeric IgG4 monoclonal antibody (mAb), was engineered to remove T-cell epitopes to reduce immunogenicity risk. Andecaliximab selectively binds and inhibits matrix metalloproteinase-9 (MMP9) with minimal cross-reactivity to other matrix metalloproteinases, including the highly homologous matrix metalloproteinase-2 (MMP-2). Andecaliximab is under development for the treatment of cystic fibrosis, gastric cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), rheumatoid arthritis (RA), Crohn's disease (CD), and ulcerative colitis (UC). In a recent phase 1 dose-escalation study in patients with UC, andecaliximab had good tolerability and was associated with a numerically greater percentage of clinical, endoscopic, and histological responses in patients relative to placebo over a 5-week treatment period. A phase 2\/3 trial, evaluating the safety and efficacy of andecaliximab to induce and maintain clinical remission in patients with moderate to severe UC, was initiated. A planned interim futility analysis following an 8-week induction period in the first 150 patients resulted in the termination of the study due to lack of efficacy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative Names\u003c\/th\u003e\n\u003ctd\u003eGS-5745, CAS: 1518996-49-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003e2-8 ℃\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003ctd\u003eFor Research Use Only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"AntibodySystem","offers":[{"title":"96 T","offer_id":52602771996896,"sku":"KDD06801","price":1128.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0601\/9330\/8896\/files\/AntibodySystem_63bee194-c995-49da-93ca-72f3385a39e7.png?v=1778468391","url":"https:\/\/rndmate.com\/products\/antibodysystem-kdd06801","provider":"알앤디메이트","version":"1.0","type":"link"}